Longer-Lasting eye injection could cut treatment visits for macular disease

This study looks at whether switching to a higher-dose eye injection called aflibercept 8 mg can allow people with neovascular age-related macular degeneration (nAMD) or diabetic macular oedema (DME) to go longer between treatments. It follows adults in Portugal who have already had eye injections and are now switched to aflibercept 8 mg as part of their usual care. Researchers will track how long the effect lasts, how well vision holds up, and any side effects, using data from routine clinic visits.